Accrufer, Feraccru(ferric maltol)
Accrufer, Feraccru (ferric maltol) is a small molecule pharmaceutical. Ferric maltol was first approved as Feraccru on 2016-02-18. It has been approved in Europe to treat iron-deficiency anemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Accrufer
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ferric maltol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACCRUFER | Shield Therapeutics | N-212320 RX | 2019-07-25 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| accrufer | New Drug Application | 2023-12-06 |
| ilia super serum skin tint (st10 porto ferro) | C200263 | 2024-10-25 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FERRIC MALTOL, ACCRUFER, SHIELD TX | |||
| 2024-07-25 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | — | 1 |
| Iron-deficiency anemia | D018798 | — | D50 | — | — | — | 1 | — | 1 |
| Iron deficiencies | D000090463 | — | E61.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ferric maltol |
| INN | ferric maltol |
| Description | Ferric maltol, sold under the brand names Accrufer (US) and Feraccru (EU), is an iron containing medication for the treatment of adults with low iron stores. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | Hematologic agents |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 33725-54-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298110 |
| ChEBI ID | — |
| PubChem CID | 169535 |
| DrugBank | DB15598 |
| UNII ID | MA10QYF1Z0 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,221 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
384 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use